T 0099/13 of 14.01.2016
- European Case Law Identifier
- ECLI:EP:BA:2016:T009913.20160114
- Date of decision
- 14 January 2016
- Case number
- T 0099/13
- Petition for review of
- -
- Application number
- 01981824.4
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen (C)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS
- Applicant name
- Genentech, Inc.
Novartis AG - Opponent name
- Arecor Limited
UCB PHARMA S.A.
Ablynx N.V.
SANOFI
Boehringer Ingelheim Pharma GmbH & Co. KG/
Boehringer Ingelheim International GmbH
Octapharma AG
Dr. Martin Huenges/, Dr. Lüder Behrens
Baxter Healthcare S.A.
AbbVie Bioresearch Center Inc.
Synthon B.V. - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111(1)European Patent Convention Art 123(2)European Patent Convention R 101(1)
- Keywords
- Admissibility of appeal - appeal sufficiently substantiated (yes)
Amendments - added subject-matter (no)
Appeal decision - remittal to the department of first instance (yes) - Catchword
- see point 2.3
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division for further prosecution.